We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
YM BioSciences has been advised by its European partner, Oncoscience AG, that
the Phase II trial in children with brain cancer (glioma) utilizing the EGF
receptor monoclonal antibody (h-R3) as a monotherapy achieved the clinical milestone
that permits conversion of the trial into a pivotal trial in this population.
MedImmune has filed an investigational new drug (IND) application to begin
clinical studies of its respiratory syncytial virus (RSV) and parainfluenza
virus Type-3 (PIV-3) candidate vaccine.
Dharmacon, a leading supplier of innovative RNA and RNA interference (RNAi)
research products, has announced that Genentech has selected Dharmacon's advanced
RNAi technology for use in its drug discovery and development research.
Clinical trials have been initiated for the most advanced compound in the
drug discovery and development collaboration between Merck & Co. and Karo
Bio.
Peregrine Pharmaceuticals and the New Approaches to Brain Tumor Therapy (NABTT)
Consortium have received approval from the National Cancer Institute (NCI)
for their clinical protocol to treat Glioblastoma Multiforme, a deadly form
of brain cancer, using Cotara.
Genaissance Pharmaceuticals has said a study it conducted on 674 subjects
suggests that women with a genetic predisposition to protective levels of
C-reactive protein (CRP) lose that benefit when taking hormone replacement
therapy (HRT).
Immtech International has announced that enrollment was initiated for a Phase
I volunteer human trial to evaluate two new formulations of DB289, its first
oral drug candidate.
Tapestry Pharmaceuticals has announced that the FDA has raised no objections
that would preclude the company from entering Phase I clinical trials for its
investigational new drug, TPI 287, a novel proprietary taxane.
Serono Inc., the U.S. affiliate of global biotechnology leader Serono, has completed
enrollment in its second multicenter, Phase III trial of Serostim in the treatment
of HIV-Associated Adipose Redistribution Syndrome (HARS).